Expression of autophagy marker in peripheral blood T and B lymphocytes of patients with autoimmune hepatitis and its clinical significance

Huili WU; Hongbo SHI; Yanmin LIU; Yan YAN; Lingling WANG; Mei DING; Zhenglai MA; Hui LIU; Zhongping DUAN

doi:10.3969/j.issn.1001-5256.2022.11.009

Volume 38 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(11): 2483-2487

PDF( 1886 KB)

Expression of autophagy marker in peripheral blood T and B lymphocytes of patients with autoimmune hepatitis and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2022.11.009

Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

Beijing Advanced Innovation Center for Big Data-Based Precision Medicine (PXM2021-014226-000026);

Capital's Funds for Health Improvement and Research (2021-1G-2181);

Incubation Project for Young and Middle-Aged Talents of Beijing YouAn Hospital, Capital Medical University (YNKTQN2021008)

More Information

Corresponding author: DUAN Zhongping, duan@ccmu.edu.cn(ORCID: 0000-0002-2188-9692)
Received Date: 2022-04-26
Accepted Date: 2022-05-30
Published Date: 2022-11-20

Abstract

Abstract

Objective To investigate the expression of autophagy marker in peripheral blood T and B lymphocytes of patients with autoimmune hepatitis (AIH) and its clinical significance. Methods Peripheral blood samples were collected from 62 AIH patients who were treated in Beijing YouAn Hospital affiliated to Capital Medical University from October 2019 to October 2020 who were treated in Beijing YouAn Hospital affiliated to Capital Medical University from October 2019 to October 2020 and 8 healthy controls to detect autophagy of T and B lymphocyte subsets, and then subgroup analyses were performed based on treatment, diagnostic type, and presence or absence of liver cirrhosis and liver failure. The t-test was used for comparison of normally distributed continuous data between two groups; the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups, and the Mann-Whitney U test was used for comparison between two groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between two groups. Results Compared with the healthy control group, the AIH group had a significantly higher mean fluorescence intensity (MFI) of the autophagy marker LC3B in CD4⁺ T, CD8⁺ T, CD19⁺ B, and CD4⁺CD25⁺ T lymphocytes (all P < 0.05), especially in CD19⁺ B lymphocytes. The non-treatment group and the partial remission group had a significantly higher MFI of autophagy marker in CD19⁺ B lymphocytes than the complete remission group (P=0.037 and 0.040); the idiopathic AIH (I-AIH) group and the drug-induced AIH(DI-AIH) group had a significantly higher MFI than the primary biliary cholangitis (PBC)-AIH overlap syndrome group (P=0.037 and 0.031); the non-cirrhosis group and the decompensated cirrhosis group had a significantly higher MFI than the compensated cirrhosis group (P=0.009 and 0.003); the liver failure group had a significantly higher MFI than the non-liver failure group (P=0.042). The PBC-AIH group had a significantly higher MFI of autophagy marker in CD4⁺CD25⁺ T lymphocytes than the I-AIH group and the DI-AIH group (P=0.042 and 0.044), the compensated cirrhosis group had a significantly lower MFI than the non-cirrhosis group (P=0.037), and the non-liver failure group had a significantly higher MFI than the liver failure group (P=0.043). Conclusion AIH patients have a significant increase in the expression of autophagy marker in peripheral blood T and B lymphocyte subsets compared with healthy individuals, and the level of autophagy is associated with treatment, diagnostic type, and disease severity.
- Hepatitis, Autoimmune,
- Lymphocytes,
- Autophagy

FullText(HTML)

References(22)

References

[1]	LIBERAL R, de BOER YS, ANDRADE RJ, et al. Expert clinical management of autoimmune hepatitis in the real world[J]. Aliment Pharmacol Ther, 2017, 45(5): 723-732. DOI: 10.1111/apt.13907.
[2]	ALVAREZ F, BERG PA, BIANCHI FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31(5): 929-938. DOI: 10.1016/s0168-8278(99)80297-9.
[3]	HENNES EM, ZENIYA M, CZAJA AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology (Baltimore, Md), 2008, 48(1): 169-176. DOI: 10.1002/hep.22322.
[4]	WEILER-NORMANN C, SCHRAMM C. Drug induced liver injury and its relationship to autoimmune hepatitis[J]. J Hepatol, 2011, 55(4): 747-749. DOI: 10.1016/j.jhep.2011.02.024.
[5]	YEONG TT, LIM KH, GOUBET S, et al. Natural history and outcomes in drug-induced autoimmune hepatitis[J]. Hepatol Res, 2016, 46(3): E79-E88. DOI: 10.1111/hepr.12532.
[6]	CHAZOUILLÈRES O, WENDUM D, SERFATY L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy[J]. Hepatology, 1998, 28(2): 296-301. DOI: 10.1002/hep.510280203.
[7]	BOBERG KM, CHAPMAN RW, HIRSCHFIELD GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue[J]. J Hepatol, 2011, 54(2): 374-385. DOI: 10.1016/j.jhep.2010.09.002.
[8]	SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3.
[9]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
[10]	FUKUI H, SAITO H, UENO Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015[J]. J Gastroenterol, 2016, 51(7): 629-650. DOI: 10.1007/s00535-016-1216-y.
[11]	LEBINE B, MIZUSHIMA N, VIRGIN HW. Autophagy in immunity and inflammation[J]. Nature, 2011, 469(7330): 323-335. DOI: 10.1038/nature09782.
[12]	WANG WR, TANG XD. Research progress of autophagy in the prevention and treatment of malignant hematologic diseases[J]. China Med Herald, 2021, 18(33): 35-39. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202133008.htm 王文儒, 唐旭东. 自噬在恶性血液病防治过程中的研究进展[J]. 中国医药导报, 2021, 18(33): 35-39. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202133008.htm
[13]	WU DJ, ADAMOPOULOS IE. Autophagy and autoimmunity[J]. Clin Immunol, 2017, 176: 55-62. DOI: 10.1016/j.clim.2017.01.007.
[14]	CHEN YW, WANG C, WANG XG, et al. Levels of autophagy in T cells and B cell of patients with systemic lupus erythematosus and its clinical significance[J]. Chin J Immunol, 2015, 31(10): 1380-1384. DOI: 10.3969/j.issn.1000-484X.2015.10.018. 陈燕文, 王超, 王旭光, 等. 系统性红斑狼疮患者外周血T、B细胞自噬水平及其临床意义[J]. 中国免疫学杂志, 2015, 31(10): 1380-1384. DOI: 10.3969/j.issn.1000-484X.2015.10.018.
[15]	CLARKE AJ, ELLINGHAUS U, CORTINI A, et al. Autophagy is activated in systemic lupus erythematosus and required for plasmablast development[J]. Ann Rheum Dis, 2015, 74(5): 912-920. DOI: 10.1136/annrheumdis-2013-204343.
[16]	HAMPE CS. B cell in autoimmune diseases[J]. Scientifica (Cairo), 2012, 2012: 215308. DOI: 10.6064/2012/215308.
[17]	BRANDÃO DF, RAMALHO FS, MARTINELLI AL, et al. Relationship between plasma cells and hepatic stellate cells in autoimmune hepatitis[J]. Pathol Res Pract, 2010, 206(12): 800-804. DOI: 10.1016/j.prp.2010.08.002.
[18]	RADBRUCH A, MUEHLINGHAUS G, LUGER EO, et al. Competence and competition: the challenge of becoming a long-lived plasma cell[J]. Nat Rev Immunol, 2006, 6(10): 741-750. DOI: 10.1038/nri1886.
[19]	CARO-MALDONADO A, WANG R, NICHOLS AG, et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells[J]. J Immunol, 2014, 192(8): 3626-3636. DOI: 10.4049/jimmunol.1302062.
[20]	TORIGOE M, IWATA S, NAKAYAMADA S, et al. Metabolic reprogramming commits differentiation of human CD27⁺IgD⁺ B cells to plasmablasts or CD27^-IgD^- cells[J]. J Immunol, 2017, 199(2): 425-434. DOI: 10.4049/jimmunol.1601908.
[21]	PENGO N, SCOLARI M, OLIVA L, et al. Plasma cells require autophagy for sustainable immunoglobulin production[J]. Nat Immunol, 2013, 14(3): 298-305. DOI: 10.1038/ni.2524.
[22]	RAZA I, CLARKE AJ. B cell metabolism and autophagy in autoimmunity[J]. Front Immunol, 2021, 12: 681105. DOI: 10.3389/fimmu.2021.681105.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(6)

Get Citation

PDF

XML

Article Metrics

Article views (670) PDF downloads(54)

Expression of autophagy marker in peripheral blood T and B lymphocytes of patients with autoimmune hepatitis and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2022.11.009

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Expression of autophagy marker in peripheral blood T and B lymphocytes of patients with autoimmune hepatitis and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2022.11.009

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content